愛美客(300896.SZ):注射用A型肉毒毒素的註冊上市許可已獲受理
格隆匯7月3日丨愛美客(300896.SZ)公佈,公司近日收到國家藥品監督管理局下發的《受理通知書》(受理號:JXSS2400051),獲悉公司申請的境外生產藥品註冊上市許可已獲受理,產品名稱為注射用A型肉毒毒素。
隨着行業的不斷髮展,公司通過差異化定位,加大研發力度,形成了不同產品間的優勢互補,滿足不同層次的客户的需求。注射用A型肉毒毒素上市後將與公司現有醫療器械產品相互協同,提供更完善的醫療美容產品供應,滿足日益多元化的市場需求,提升品牌影響力和核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.